SCHEMBL23964132

SCHEMBL23964132

Fc1cncnc1N1CCN(Cc2nc3ccccc3o2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 6/20 0.45
DRD2 P14416 4/20 0.45
DRD4 P21917 3/20 0.45
KCNH2 Q12809 1/20 0.42
DRD1 P21728 2/20 0.42
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 2/20 0.40
TNF P01375 2/20 0.40
NOD1 Q9Y239 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23932587 0.87 DRD3 (0.48) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL25505782 0.86 DRD3 (0.45) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL23932551 0.86 HSD11B1 (0.44) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL30297605 0.86 HSD11B1 (0.44) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL28962374 0.84 DRD4 (0.45) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL30040502 0.84 DRD4 (0.45) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL23932549 0.81 LMNA (0.46) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL30297594 0.81 LMNA (0.46) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL23932495 0.79 MAPK1 (0.46) DRD3DRD2DRD4KCNH2DRD1
SCHEMBL30041262 0.79 MAPK1 (0.46) DRD3DRD2DRD4KCNH2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 DRD3 4747/4885DRD2 4780/4885DRD4 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.